From mitochondrial biology to magic bullet: Navitoclax disarms BCL-2 in chronic lymphocytic leukemia

Journal of Clinical Oncology

Volumn 30, Issue 5, 2012, Pages 554-557

  Walensky, Loren D ^a  

^a DANA FARBER CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

NAVITOCLAX; PROTEIN BCL 2;

APOPTOSIS; CANCER RESISTANCE; CHROMOSOME TRANSLOCATION; CHRONIC LYMPHATIC LEUKEMIA; CYTOLOGY; DRUG MECHANISM; DRUG TARGETING; HUMAN; MITOCHONDRION; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; SHORT SURVEY; THROMBOCYTOPENIA;

ANILINE COMPOUNDS; ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; DRUG RESISTANCE, NEOPLASM; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; MITOCHONDRIA; PROTO-ONCOGENE PROTEINS C-BCL-2; SULFONAMIDES;

EID: 84856879033     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2011.37.9339     Document Type: Short Survey

References (26)

1. Roberts AW, Seymour JF, Brown JR, et al: Substantial susceptibility of chronic lymphocytic leukemia to BCL2 inhibition: Results of a phase I study of navitoclax in patients with relapsed or refractory disease. J Clin Oncol 30:488-496, 2012
2. Tsujimoto Y, Finger LR, Yunis J, et al: Cloning of the chromosome breakpoint of neoplastic B cells with the t(14;18) chromosome translocation. Science 226:1097-1099, 1984 (Pubitemid 15217831)
3. Pegoraro L, Palumbo A, Erikson J, et al: A 14;18 and an 8;14 chromosome translocation in a cell line derived from an acute B-cell leukemia. Proc Natl Acad Sci U S A 81:7166-7170, 1984 (Pubitemid 15216717)
4. Wang K, Gross A, Waksman G, et al: Mutagenesis of the BH3 domain of BAX identifies residues critical for dimerization and killing. Mol Cell Biol 18:6083-6089, 1998 (Pubitemid 28450559)
5. Sattler M, Liang H, Nettesheim D, et al: Structure of Bcl-xL-Bak peptide complex: Recognition between regulators of apoptosis. Science 275: 983-986, 1997 (Pubitemid 27087715)
6. Shuker SB, Hajduk PJ, Meadows RP, et al: Discovering high-affinity ligands for proteins: SAR by NMR. Science 274:1531-1534, 1996 (Pubitemid 26403929)
7. Oltersdorf T, Elmore SW, Shoemaker AR, et al: An inhibitor of Bcl-2 family proteins induces regression of solid tumours. Nature 435:677-681, 2005 (Pubitemid 40825512)
8. Tse C, Shoemaker AR, Adickes J, et al: ABT-263: A potent and orally bioavailable Bcl-2 family inhibitor. Cancer Res 68:3421-3428, 2008
9. Lee EF, Czabotar PE, Smith BJ, et al: Crystal structure of ABT-737 complexed with Bcl-xL: Implications for selectivity of antagonists of the Bcl-2 family. Cell Death Differ 14:1711-1713, 2007 (Pubitemid 47278856)
10. Petros AM, Nettesheim DG, Wang Y, et al: Rationale for Bcl-xL/Bad peptide complex formation from structure, mutagenesis, and biophysical studies. Protein Sci 9:2528-2534, 2000 (Pubitemid 32105735)
11. Zhang H, Nimmer PM, Tahir SK, et al: Bcl-2 family proteins are essential for platelet survival. Cell Death Differ 14:943-951, 2007 (Pubitemid 46655455)
12. Mason KD, Carpinelli MR, Fletcher JI, et al: Programmed anuclear cell death delimits platelet life span. Cell 128:1173-1186, 2007 (Pubitemid 46427871)
13. Schoenwaelder SM, Jarman KE, Gardiner E, et al: Bcl-xL inhibitory BH3 mimetics can induce a transient thrombocytopathy that undermines the hemostatic function of platelets. Blood 118:1663-1674, 2011
14. Petros AM, Huth JR, Oost T, et al: Discovery of a potent and selective Bcl-2 inhibitor using SAR by NMR. Bioorg Med Chem Lett 20:6587-6591, 2010
15. Konopleva M, Contractor R, Tsao T, et al: Mechanisms of apoptosis sensitivity and resistance to the BH3 mimetic ABT-737 in acute myeloid leukemia. Cancer Cell 10:375-388, 2006 (Pubitemid 44693472)
16. van Delft MF, Wei AH, Mason KD, et al: The BH3 mimetic ABT-737 targets selective Bcl-2 proteins and efficiently induces apoptosis via Bak/Bax if Mcl-1 is neutralized. Cancer Cell 10:389-399, 2006 (Pubitemid 44711953)
17. Merino D, Giam M, Hughes PD, et al: The role of BH3-only protein Bim extends beyond inhibiting Bcl-2-like prosurvival proteins. J Cell Biol 186:355-362, 2009
18. Chen L, Willis SN, Wei A, et al: Differential targeting of prosurvival Bcl-2 proteins by their BH3-only ligands allows complementary apoptotic function. Mol Cell 17:393-403, 2005 (Pubitemid 40193310)
19. Certo M, Del Gaizo Moore V, Nishino M, et al: Mitochondria primed by death signals determine cellular addiction to antiapoptotic BCL-2 family members. Cancer Cell 9:351-365, 2006 (Pubitemid 43668734)
20. Walensky LD, Pitter K, Morash J, et al: A stapled BID BH3 helix directly binds and activates BAX. Mol Cell 24:199-210, 2006 (Pubitemid 44557124)
21. Stewart ML, Fire E, Keating AE, et al: The MCL-1 BH3 helix is an exclusive MCL-1 inhibitor and apoptosis sensitizer. Nat Chem Biol 6:595-601, 2010
22. Nguyen M, Marcellus RC, Roulston A, et al: Small molecule obatoclax (GX15-070) antagonizes MCL-1 and overcomes MCL-1-mediated resistance to apoptosis. Proc Natl Acad Sci U S A 104:19512-19517, 2007
23. Moretti L, Li B, Kim KW, et al: AT-101, a pan-Bcl-2 inhibitor, leads to radiosensitization of non-small cell lung cancer. J Thorac Oncol 5:680-687, 2010
24. Lin X, Morgan-Lappe S, Huang X, et al: "Seed"analysis of off-target siRNAs reveals an essential role of Mcl-1 in resistance to the small-molecule Bcl-2/Bcl-XL inhibitor ABT-737. Oncogene 26:3972-3979, 2007 (Pubitemid 46884293)
25. Wilson WH, O'Connor OA, Czuczman MS, et al: Navitoclax, a targeted high-affinity inhibitor of BCL-2, in lymphoid malignancies: A phase 1 dose-escalation study of safety, pharmacokinetics, pharmacodynamics, and antitumour activity. Lancet Oncol 11:1149-1159, 2010
26. Gandhi L, Camidge DR, Ribeiro de Oliveira M, et al: Phase I study of Navitoclax (ABT-263), a novel Bcl-2 family inhibitor, in patients with small-cell lung cancer and other solid tumors. J Clin Oncol 29:909-916, 2011